- Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study. [Journal Article]
- JPJ Pediatr Urol 2019 Jun 05
- CONCLUSIONS: Despite some evidence to support BtA/EMDA in children with NDO, the authors were unable to replicate previously published positive cystometric and symptomatic outcomes. In addition, BtA/EMDA performed poorly when compared with conventional intravesical BtA injections. This implies failure of EMDA to deliver BtA correctly to the target tissue. The large size of the BtA molecule or the abnormal bladder wall in NDO could account for the negative results. Thorough preparation and consultation was undertaken before this study with BtA/EMDA, and it is discouraging that the authors were unable to reproduce the positive results of other groups.Although safe and acceptable to most patients, the authors cannot recommend the use of BtA/EMDA for NDO in children at present.
- Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older-A Population-Based Cohort Study. [Journal Article]
- JIMJAMA Intern Med 2019 Jul 15
- Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE. [Journal Article]
- IJInt J Urol 2019 Jul 14
- CONCLUSIONS: Patients aged ≥65 years receiving mirabegron in clinical practice reported clinically meaningful improvements in quality of life.
- Diagnosis and Management of Autonomic Dysfunction in Dementia Syndromes. [Review]
- CTCurr Treat Options Neurol 2019 Jul 10; 21(8):38
- Autonomic dysfunction is common in dementia, particularly in the Lewy body dementias. This review considers the evidence for autonomic dysfunction in dementia, common symptoms and potential managemen…
Autonomic dysfunction is common in dementia, particularly in the Lewy body dementias. This review considers the evidence for autonomic dysfunction in dementia, common symptoms and potential management options.
- Mirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile response. [Journal Article]
- EJEur J Pharmacol 2019 Jun 19; 858:172447
- Mirabegron is the first β3-adrenoceptor agonist approved on the market and may offer beneficial pharmacological action in patients with overactive bladder and erectile dysfunction. Here, we further i…
Mirabegron is the first β3-adrenoceptor agonist approved on the market and may offer beneficial pharmacological action in patients with overactive bladder and erectile dysfunction. Here, we further investigate the mechanisms by which mirabegron induces rat corpus cavernosum (CC) relaxation. Adult male Wistar rats were used. The CC were isolated for in vitro functional assays and β-adrenoceptors subtypes mRNA expression evaluation. Animals were treated orally with mirabegron (30 mg/kg, 3 h), tadalafil (10 mg/kg, 3 h) or both for intracavernous pressure (ICP). Intracellular levels of cAMP and cGMP were also determined. The β1-, β2- and β3-adrenoceptors subtypes were expressed in rat CC. Mirabegron produced concentration-dependent CC relaxations that were unaffected by the β1-, β2- or β3-adrenoceptor antagonists atenolol (1 μM), ICI-118,551 (1 μM) and L748,337 (10 μM), respectively. Mirabegron-induced relaxations were not affected by the phosphodiesterase type 4 inhibitor, rolipram, or the adenylyl cyclase selective inhibitor, SQ 22,536. Potassium channel- or calcium influx-blockade are not involved in mirabegron-induced relaxations. In contrast, mirabegron produced rightward shifts in the contractile response induced by the α1-adrenoceptor agonist, phenylephrine. Finally, cavernous nerve stimulation caused frequency-dependent ICP increases, which were significantly increased in rats treated with mirabegron in a similar degree of tadalafil-treated rat, without promoting a significant cAMP or cGMP accumulation. Together, our results demonstrate that mirabegron induced CC relaxation through α1-adrenoceptor blockade. Care should be taken to translate the effect of mirabegron into the clinic, especially when using rat as an animal model of erectile dysfunction.
- Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). [Journal Article]
- ATAdv Ther 2019 Jun 20
- CONCLUSIONS: There are no differences between mirabegron and antimuscarinics in terms of patient-reported OAB symptom bother and HRQoL.
- Serum sickness-like reaction associated with mirabegron. [Case Reports]
- JCJAAD Case Rep 2019; 5(6):537-539
- A Nordic registry-based study of drug treatment patterns in overactive bladder patients. [Journal Article]
- SJScand J Urol 2019 Jun 14; :1-9
- CONCLUSIONS: Treatment patterns in patients with OAB picking up a mirabegron or antimuscarinic prescription in Denmark, Norway and Sweden indicate that persistence remains a challenge.
- Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia. [Journal Article]
- POPharmacoecon Open 2019 Jun 05
- CONCLUSIONS: Mirabegron is a cost effective alternative to oxybutynin and tolterodine from the perspective of a third-party payer in Colombia.
New Search Next
- RE: Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. [Letter]
- NUNeurourol Urodyn 2019 Jun 03